BAM
ORMP icon

Belpointe Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Belpointe Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-800
Closed -$1.74K – 2469
2023
Q1 		$1.74K Sell
800
-29,100
-97% -$92.4K ﹤0.01% 3341
2022
Q4 		$360K Buy
+29,900
New +$232K 0.02% 661

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Belpointe Asset Management's ORMP Position: Q2 2023 in Review

Belpointe Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 800 shares — an estimated $1.74K sold.

Belpointe Asset Management first reported a position in ORMP in Q4 2022 and held it in 2 quarters. The position peaked at $360K in Q4 2022. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Belpointe Asset Management reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 800 Oramed Pharmaceuticals shares in Q2 2023, an estimated $1.74K.
  • Belpointe Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Oramed Pharmaceuticals position peaked at $360K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.